Clinical Summary: Kerendia for HF LVEF >= 40%

Kerendia (finerenone) is the first and only non-steroidal mineralocorticoid receptor antagonist (nsMRA) approved for adult patients with HF LVEF > 40%. By selectively blocking MR overactivation, Kerendia addresses early and sustained disease drivers to reduce the risk of cardiovascular (CV) death and HF hospitalization.

Every patient touchpoint represents an opportunity to initiate treatment⁴. Whether a patient is newly diagnosed, attending a scheduled follow-up, or has been recently hospitalized, adding Kerendia 10mg or 20mg to a multimodal strategy provides proven risk reduction regardless of comorbidities or prior treatment. Given that 2 in 3 patients are rehospitalized within one year of discharge, making Kerendia a core pillar of care is essential for keeping patients out of the hospital and improving longevity